<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REVATIO- sildenafil citrate tablet, film coated </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use REVATIO safely and effectively. See full prescribing information for REVATIO.<br> <br>REVATIO (sildenafil) tablets, REVATIO (sildenafil) injection<br>Initial U.S. Approval: 1998</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id_f588b180-3e84-4ee2-95fd-8a711fc1227b"></a><table>
<col align="left" width="70%">
<col align="right" width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Indications and Usage (<a href="#i4i_indications_ID_s1">1</a>)</td>
<td align="left" valign="top">11/2010</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions (<a href="#i4i_section_ID_s5.8">5.8</a>)</td>
<td align="left" valign="top">11/2010</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Dosage and Administration (<a href="#i4i_dosage_admin_ID_s2">2</a>)</td>
<td align="left" valign="top">11/2009</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">REVATIO is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominately patients with NYHA Functional Class II-III symptoms and etiologies of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> (71%) or <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> associated with connective tissue disease (25%). </p>
<p class="Highlighta">Limitation of use: The efficacy of REVATIO has not been adequately evaluated in patients taking bosentan concurrently. (<a href="#i4i_indications_ID_s1">1</a>) </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Tablets: 20 mg three times a day, approximately 4–6 hours apart, with or without food. (<a href="#i4i_section_ID_s2.1">2.1</a>). Higher doses not recommended. (<a href="#i4i_section_ID_s2.1">2.1</a>)</li>
<li>Injection: 10 mg (12.5 mL) three times a day administered as an IV bolus injection. (<a href="#i4i_section_ID_s2.1">2.1</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Tablets: 20 mg (<a href="#i4i_dosage_form_strength_ID_s3">3</a>)</li>
<li>Injection: 10 mg (12.5 mL) single use vial. (<a href="#i4i_dosage_form_strength_ID_s3">3</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Use with organic nitrates. (<a href="#i4i_section_ID_s4.1">4.1</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to sildenafil or any component of the tablet. (<a href="#i4i_section_ID_s4.2">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Cardiovascular effects: Carefully consider whether patients with certain underlying conditions (e.g., resting <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, fluid depletion) could be adversely affected by vasodilatory effects of REVATIO. Not recommended in patients with pulmonary veno-occlusive disease. (<a href="#i4i_section_ID_s5.1">5.1</a>)</li>
<li>Use with alpha-blockers: Note additive blood pressure-lowering effects. (<a href="#i4i_section_ID_s5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: In patients with PAH secondary to CTD, higher rates of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> with REVATIO than placebo, including with concomitant oral vitamin K antagonists. (<a href="#i4i_section_ID_s5.2">5.2</a>)</li>
<li>Use with ritonavir and other potent CYP3A inhibitors: Coadministration not recommended. (<a href="#i4i_section_ID_s5.3">5.3</a>)</li>
<li>Effects on the eye: Consider discontinuing REVATIO if sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> occurs, which could be non-<span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">arteritic ischemic optic neuropathy</span> (NAION). (<a href="#i4i_section_ID_s5.4">5.4</a>)</li>
<li>Hearing impairment: Discontinue REVATIO if sudden decrease or loss of hearing occurs. (<a href="#i4i_section_ID_s5.5">5.5</a>)</li>
<li>Use with PDE5 inhibitors: Avoid use with VIAGRA or other PDE5 inhibitors. (<a href="#i4i_section_ID_s5.6">5.6</a>)</li>
<li>Prolonged erection: Advise patients to seek emergency treatment if an erection lasts &gt; 4 hours. Use REVATIO with caution in patients predisposed to <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>. (<a href="#i4i_section_ID_s5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span>: REVATIO may cause serious vaso-occlusive crises. (<a href="#i4i_section_ID_s5.8">5.8</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 3% and more frequent than placebo) include <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (<a href="#i4i_section_ID_s6.1">6.1</a>).  </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: No dose adjustments required (including severe impairment CLcr &lt; 30 mL/min). (<a href="#i4i_pharmacokinetics_ID_s12.3">12.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Mild to moderate require no dose adjustment. Severe has not been studied. (<a href="#i4i_pharmacokinetics_ID_s12.3">12.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> (PAH)</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Use with Organic Nitrates</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular Effects</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Effects on <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use with Ritonavir and Other Potent CYP3A Inhibitors</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Effects on the Eye</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hearing Impairment</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Combination with other PDE5 inhibitors</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Prolonged Erection</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension Secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">REVATIO® is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when REVATIO was added to background epoprostenol therapy.</p>
<p style="border-left:1px solid;"><span class="XmChange">Studies establishing effectiveness included predominately patients with NYHA Functional Class II-III symptoms and etiologies of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> (71%) or <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> associated with connective tissue disease (25%).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba62b3c1-f400-4139-b4df-f680aef757f2"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Italics">Limitation of Use</span></p>
<p>The efficacy of REVATIO has not been adequately evaluated in patients taking bosentan concurrently.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span> (PAH)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4b27727-8355-4fa5-b9b1-69a6166c1604"></a><a name="section-2.1.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange">REVATIO Tablets</span></p>
<p>The recommended dose of REVATIO is 20 mg three times a day (TID). REVATIO tablets should be taken approximately 4–6 hours apart, with or without food. </p>
<p>In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended. Dosages lower than 20 mg TID were not tested. Whether dosages lower than 20 mg TID are effective is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d244db3a-0c25-404b-b98f-fff48ce746cf"></a><a name="section-2.1.2"></a><p></p>
<p class="First">REVATIO Injection</p>
<p>REVATIO injection is for the continued treatment of patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH) who are currently prescribed oral REVATIO and who are temporarily unable to take oral medication.</p>
<p>The recommended dose is 10 mg (corresponding to 12.5 mL) administered as an intravenous bolus injection three times a day. The dose of REVATIO injection does not need to be adjusted for body weight.</p>
<p>A 10 mg dose of REVATIO injection is predicted to provide pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_ID_s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_313927b1-90b5-4252-afcd-2c45eda19be7"></a><a name="section-3.1"></a><p></p>
<p class="First">REVATIO Tablets</p>
<p>REVATIO tablets are supplied as white, film-coated, round tablets engraved with "RVT20" containing sildenafil citrate equivalent to 20 mg of sildenafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d8100ae-adab-45fe-8b49-772539dc4c9e"></a><a name="section-3.2"></a><p></p>
<p class="First">REVATIO Injection</p>
<p>REVATIO injection is supplied as a single use vial containing 10 mg (12.5 mL) of sildenafil.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Use with Organic Nitrates</h2>
<p class="First">Do not use REVATIO in patients taking organic nitrates in any form, either regularly or intermittently. Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">REVATIO is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sildenafil or any component of the tablet or injection.</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported in association with the use of sildenafil including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> events and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>. The majority of reported events were non-serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_ID_s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular Effects</h2>
<p class="First">REVATIO has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing REVATIO, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients with resting <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> [BP &lt; 90/50], fluid depletion, severe left ventricular outflow obstruction, or <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic dysfunction</span>).</p>
<p>Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. Should signs of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> occur when REVATIO is administered, consider the possibility of associated PVOD.</p>
<p>As there are no controlled clinical data on the safety or efficacy of REVATIO in the following groups, prescribe with caution for:</p>
<ul>
<li>Patients who have suffered a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> within the last 6 months;</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> causing <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>;</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (BP &gt; 170/110);</li>
<li>Patients currently on bosentan therapy.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6737bf69-e3be-405c-b9de-0b6ab727e033"></a><a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Italics">Use with Alpha-blockers</span></p>
<p>PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly, leading to symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In the sildenafil interaction studies with alpha-blockers, cases of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> consisting of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> were reported <span class="Italics">[see <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a>]</span>. No cases of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> were reported during these interaction studies. The safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> and concomitant use of anti-hypertensive drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Effects on <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">In humans, sildenafil has no effect on <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> when taken alone or with aspirin. In vitro studies with human platelets indicate that sildenafil potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide donor). The combination of heparin and sildenafil had an additive effect on <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in the anesthetized rabbit, but this interaction has not been studied in humans.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> was 13% in patients taking sildenafil with PAH secondary to connective tissue disease (CTD). This effect was not seen in <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> (PPH) (sildenafil 3%, placebo 2%) patients. The incidence of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> was also higher in sildenafil-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).</p>
<p>The safety of REVATIO is unknown in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders or active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use with Ritonavir and Other Potent CYP3A Inhibitors</h2>
<p class="First">The concomitant administration of the protease inhibitor ritonavir (a highly potent CYP3A inhibitor) substantially increases serum concentrations of sildenafil; therefore, co-administration of ritonavir or other potent CYP3A inhibitors with REVATIO is not recommended <span class="Italics">[see <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Effects on the Eye</h2>
<p class="First">Advise patients to seek immediate medical attention in the event of a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes while taking PDE5 inhibitors, including REVATIO. Such an event may be a sign of non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, that has been reported postmarketing in temporal association with the use of all PDE5 inhibitors, including sildenafil, when used in the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE5 inhibitors <span class="Italics">[see <a href="#i4i_section_ID_s6.2">Adverse Reactions (6.2)</a>]</span>.</p>
<p>There are no controlled clinical data on the safety or efficacy of REVATIO in patients with <span class="product-label-link" type="condition" conceptid="4103381" conceptname="Retinitis pigmentosa">retinitis pigmentosa</span>, a minority whom have genetic disorders of retinal phosphodiesterases. Prescribe REVATIO with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hearing Impairment</h2>
<p class="First">Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE5 inhibitors, including REVATIO. These events, which may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, have been reported in temporal association to the intake of PDE5 inhibitors, including REVATIO. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors <span class="Italics">[see <a href="#i4i_section_ID_s6.2">Adverse Reactions (6.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Combination with other PDE5 inhibitors</h2>
<p class="First">Sildenafil is also marketed as VIAGRA®. The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE5 inhibitors have not been studied. Inform patients taking REVATIO not to take VIAGRA or other PDE5 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Prolonged Erection</h2>
<p class="First">Use REVATIO with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, or Peyronie's disease) or in patients who have conditions, which may predispose them to <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (e.g., <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>). In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (<span class="product-label-link" type="condition" conceptid="4213599" conceptname="Painful penile erection">painful erection</span> greater than 6 hours in duration) is not treated immediately, penile tissue damage and permanent loss of potency could result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension Secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In a small, prematurely terminated study of patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> (PH) secondary to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span>, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received REVATIO than by those randomized to placebo. The effectiveness of REVATIO in PH secondary to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> has not been established.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Vision loss</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Vaso-occlusive crisis [see <span class="Italics"><a href="#i4i_section_ID_s5.8">Warnings and Precautions (5.8)</a></span>] </li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Safety data were obtained from the 12 week, placebo-controlled clinical study and an open-label extension study in 277 treated patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>. Doses up to 80 mg TID were studied.</p>
<p>The overall frequency of discontinuation in REVATIO-treated patients at the recommended dose of 20 mg TID was 3% and was the same for the placebo group.</p>
<p>In the placebo-controlled trial in <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, the adverse drug reactions that were reported by at least 3% of REVATIO patients treated at the recommended dosage (20 mg TID) and were more frequent in REVATIO patients than placebo patients, are shown in Table 1. Adverse events were generally transient and mild to moderate in nature.</p>
<a name="table1"></a><table>
<caption><span>Table 1. REVATIO All Causality Adverse Events in ≥ 3% of Patients and More Frequent (&gt; 1%) than Placebo</span></caption>
<col align="left" width="30%">
<col align="center" width="20%">
<col align="center" width="30%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">ADVERSE EVENT<br>%</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo<br>(n = 70)</td>
<td class="Botrule Rrule" align="left" valign="top">REVATIO 20 mg TID<br>(n = 69)</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo-<br>Subtracted</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Lrule Rrule" align="left" colspan="4" valign="top"><span class="Italics">nos: Not otherwise specified</span></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">9</td>
<td class="Rrule" align="left" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left" valign="top">39</td>
<td class="Rrule" align="left" valign="top">46</td>
<td class="Rrule" align="left" valign="top">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="left" valign="top">7</td>
<td class="Rrule" align="left" valign="top">13</td>
<td class="Rrule" align="left" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="left" valign="top">4</td>
<td class="Rrule" align="left" valign="top">10</td>
<td class="Rrule" align="left" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">7</td>
<td class="Rrule" align="left" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">6</td>
<td class="Rrule" align="left" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea exacerbated</span></td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">7</td>
<td class="Rrule" align="left" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> nos</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">4</td>
<td class="Rrule" align="left" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> nos</td>
<td class="Rrule" align="left" valign="top">6</td>
<td class="Rrule" align="left" valign="top">9</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="left" valign="top">4</td>
<td class="Rrule" align="left" valign="top">7</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">6</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span> nos</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">3</td>
</tr>
</tbody>
</table>
<p>At doses higher than the recommended 20 mg TID, there was a greater incidence of some adverse events including <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span> at the recommended sildenafil 20 mg TID dose was 1.4% versus 0% placebo and for all sildenafil doses studied was 1.9% versus 0% placebo. The incidence of <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span> at both the recommended dose and at all doses studied was 1.4% for sildenafil versus 1.4% for placebo. The patients experiencing these events had risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> including concurrent anticoagulant therapy. </p>
<p>In a placebo-controlled fixed dose titration study of REVATIO (starting with recommended dose of 20 mg TID and increased to 40 mg TID and then 80 mg TID) as an adjunct to intravenous epoprostenol in <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, the adverse events that were reported were more frequent than in the placebo arm (&gt; 6% difference) are shown in Table 2.</p>
<a name="table2"></a><table>
<caption><span>Table 2. REVATIO-Epoprostenol Adverse Events More Frequent (&gt; 6%) than Placebo</span></caption>
<col align="left" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">ADVERSE EVENT<br>%</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo + Epoprostenol<br>(n = 131)</td>
<td class="Botrule Rrule" align="left" valign="top">REVATIO + Epoprostenol<br>(n = 134)</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Placebo- Subtracted<br>%</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule" align="left" valign="top">34</td>
<td class="Toprule" align="left" valign="top">57</td>
<td class="Rrule" align="left" valign="top">23</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="left" valign="top">13</td>
<td align="left" valign="top">25</td>
<td class="Rrule" align="left" valign="top">14</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="left" valign="top">2</td>
<td align="left" valign="top">16</td>
<td class="Rrule" align="left" valign="top">14</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="left" valign="top">6</td>
<td align="left" valign="top">17</td>
<td class="Rrule" align="left" valign="top">11</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="top">18</td>
<td align="left" valign="top">25</td>
<td class="Rrule" align="left" valign="top">7</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left" valign="top">18</td>
<td align="left" valign="top">25</td>
<td class="Rrule" align="left" valign="top">7</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td align="left" valign="top">2</td>
<td align="left" valign="top">9</td>
<td class="Rrule" align="left" valign="top">7</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2dbb2197-25df-417b-9350-142618ce0e05"></a><a name="section-6.1.1"></a><p></p>
<p class="First">REVATIO Injection</p>
<p>REVATIO injection was studied in a 66-patient, placebo-controlled study at doses targeting plasma concentrations between 10 and 500 ng/mL (up to 8 times the exposure of the recommended dose). Adverse events in PAH patients were similar to those seen with oral tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of sildenafil (marketed for both PAH and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3cf5d39c-31a5-46a2-9606-dbdff09b4151"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Cardiovascular Events</span></p>
<p>In postmarketing experience with sildenafil at doses indicated for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, serious cardiovascular, cerebrovascular, and vascular events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, and subarachnoid and <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhages</span> have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after use concurrent with sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient's underlying cardiovascular disease, or to a combination of these or other factors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2193966a-c3a0-431c-be00-2bfd5545800f"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics">Decreases in and <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Loss of Vision</span></span></p>
<p>When used to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77b8f68d-e87c-4ccf-b014-e8920151b18c"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Italics">Loss of Hearing</span></p>
<p>Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including REVATIO. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of REVATIO, to the patient's underlying risk factors for <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, a combination of these factors, or to other factors <span class="Italics">[see <a href="#i4i_section_ID_s5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6dee17a-a529-4aaa-ac88-fa32357daec5"></a><a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Italics">Other Events </span></p>
<p>The following list includes other adverse events that have been identified during postmarketing use of REVATIO. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>Nervous system: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> recurrence</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af2ecb4c-cc77-4b86-b17a-c73827aefcd5"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Italics">Nitrates</span></p>
<p>Concomitant use of REVATIO with nitrates in any form is contraindicated <span class="Italics">[see <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ab1cf56-8659-4fbb-a1ca-cb1b54fe9afc"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Italics">Ritonavir and other Potent CYP3A Inhibitors</span></p>
<p>Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended <span class="Italics">[see <a href="#i4i_section_ID_s5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d694a8f-97f7-4e27-ae45-c2fe7e73f2c2"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Italics">Alpha-blockers</span></p>
<p>Use caution when co-administering alpha-blockers with REVATIO because of additive blood pressure-lowering effects <span class="Italics">[see <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. There were infrequent reports of patients who experienced symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. These reports included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and light-headedness, but not <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e502998c-bbed-43b7-a402-7245ed1a40ce"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Italics">Amlodipine</span></p>
<p>When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_s8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_3d00ea33-accd-4fbc-89bb-a3e155aa9cbf"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, embryotoxicity, or fetotoxicity was observed in pregnant rats or rabbits dosed with sildenafil 200 mg/kg/day during organogenesis, a level that is, on a mg/m<span class="Sup">2 </span>basis, 32- and 68-times, respectively, the recommended human dose (RHD) of 20 mg TID. In a rat pre- and postnatal development study, the no-observed-adverse-effect dose was 30 mg/kg/day (equivalent to 5-times the RHD on a mg/m<span class="Sup">2 </span>basis). There are, however, no adequate and well-controlled studies of sildenafil in pregnant women. Because animal reproduction studies are not always predictive of human response, REVATIO should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_s8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The safety and efficacy of Revatio during labor and delivery has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_s8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if sildenafil or its metabolites are excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when REVATIO is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_s8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of sildenafil in pediatric <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_s8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of REVATIO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment for mild to moderate impairment is required. Severe impairment has not been studied <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is required (including severe impairment CLcr &lt; 30 mL/min) <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but rates and severities were increased. </p>
<p>In cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">REVATIO, a therapy for <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil is also marketed as VIAGRA<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>.</p>
<p>Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1<span class="Italics">H</span>-pyrazolo [4,3-<span class="Italics">d</span>] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate and has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-01.jpg"></p>
<p>Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7.</p>
<p>REVATIO Tablets: REVATIO is formulated as white, film-coated round tablets equivalent to 20 mg of sildenafil for oral administration. In addition to the active ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, lactose monohydrate, and triacetin.</p>
<p>REVATIO Injection: REVATIO is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_ID_s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Sildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> in the systemic circulation.</p>
<p>Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels <span class="Italics">[see <a href="#i4i_pharmacodynamics_ID_s12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>
<p>In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets. The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_ID_s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19fa6ce8-7e58-4a80-895e-eed1c3b056f8"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Effects of REVATIO on Blood Pressure</span></p>
<p>Single oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1–2 hours after dosing, and was not different from placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates <span class="Italics">[see <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a>]</span>.</p>
<p>Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg TID to patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, no clinically relevant effects on ECG were reported.</p>
<p>After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively.</p>
<p>After chronic dosing of 80 mg TID sildenafil to patients with systemic <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.</p>
<p>After chronic dosing of 80 mg TID sildenafil to patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_877a714c-2acd-4f38-a1fc-d2205c026ced"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Effects of REVATIO on Vision</span></p>
<p>At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_ID_s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30cbce50-2038-4f64-a0a9-887147f6fdb7"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption and Distribution</span></p>
<p>REVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in T<span class="Sub">max</span> of 60 minutes and a mean reduction in C<span class="Sub">max</span> of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94dbf64f-bb88-4ea8-949f-5b1964a2e6a7"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Metabolism and Excretion</span></p>
<p>Sildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal half-lives of about 4 hours. </p>
<p>After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).</p>
<p>REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34f8e670-3526-4613-ab23-71df0538a6c1"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Population Pharmacokinetics</span></p>
<p>Age, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH. </p>
<p>In patients with PAH, the average steady-state concentrations were 20–50% higher when compared to those of healthy volunteers. There was also a doubling of C<span class="Sub">min</span> levels compared to healthy volunteers. Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> compared to healthy volunteers.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_033a5fb5-31f6-4cd0-bcc4-734da0008670"></a><a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Underline">Geriatric Patients</span></p>
<p>Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18–45 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_369005e0-c894-4b84-9831-14a27f03db7f"></a><a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In volunteers with mild (CLcr = 50–80 mL/min) and moderate (CLcr = 30–49 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C<span class="Sub">max</span> compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to subjects with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b64c2776-779f-4bc9-84ce-5396fe56cb09"></a><a name="section-11.3.3.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In volunteers with mild to moderate <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and C<span class="Sub">max</span> (47%) compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C) have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_30034871-2446-4cae-9866-29d4c616358b"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Drug Interaction Studies</span></p>
<p>Sildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms. Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.</p>
<p>Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 µM).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ee63fec-8741-478b-8ba9-6da5bda7fffb"></a><a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Underline">Ritonavir and other CYP3A Inhibitors</span></p>
<p>In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil C<span class="Sub">max</span> and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.</p>
<p>Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir). </p>
<p>Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. </p>
<p>When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). </p>
<p>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil C<span class="Sub">max</span> and a 210% increase in sildenafil AUC. </p>
<p>REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5634976b-a964-4286-bdb5-b12e9bd59634"></a><a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Underline">Bosentan</span></p>
<p>In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C<span class="Sub">max</span>. Co-administration resulted in a 50% increase in AUC of bosentan. The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad2dc2a2-8133-40d3-914d-134de0be9832"></a><a name="section-11.3.4.3"></a><p></p>
<p class="First"><span class="Underline">Epoprostenol</span></p>
<p>The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28f59495-9b95-4cfe-9e8a-9714148e12fb"></a><a name="section-11.3.4.4"></a><p></p>
<p class="First"><span class="Underline">CYP Substrates and Beta-blockers</span></p>
<p>Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers. </p>
<p>In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.</p>
<p>No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67cb3df0-aa9f-44ff-b0af-02a7588dfda5"></a><a name="section-11.3.4.5"></a><p></p>
<p class="First"><span class="Underline">Oral Contraceptives</span></p>
<p>Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil. Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b3496b2-071e-4190-bdba-29697e0f6f5f"></a><a name="section-11.3.4.6"></a><p></p>
<p class="First"><span class="Underline">Atorvastatin</span></p>
<p>Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0bc24de5-be2a-4c83-a6e1-8f72b3f33367"></a><a name="section-11.3.4.7"></a><p></p>
<p class="First"><span class="Underline">Antacids</span></p>
<p>Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2cb6a83f-1259-4aa4-82a6-afaf8c113da5"></a><a name="section-11.3.4.8"></a><p></p>
<p class="First"><span class="Underline">Aspirin</span></p>
<p>Sildenafil (50 mg) did not potentiate the increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> caused by aspirin (150 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4ca6d8b-f1ad-4638-a863-a61dea230994"></a><a name="section-11.3.4.9"></a><p></p>
<p class="First"><span class="Underline">Alcohol</span></p>
<p>Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_ID_s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Sildenafil was not carcinogenic when administered to rats for up to 24 months at 60 mg/kg/day, a dose resulting in total systemic exposure (AUC) to unbound sildenafil and its major metabolite 33 and 37 times, for male and female rats respectively, the human exposure at the RHD of 20 mg TID. Sildenafil was not carcinogenic when administered to male and female mice for up to 21 and 18 months, respectively, at doses up to a maximally tolerated level of 10 mg/kg/day, a dose equivalent to the RHD on a mg/m<span class="Sup">2 </span>basis.</p>
<p>Sildenafil was negative in in<span class="Italics"> vitro </span>bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and <span class="Italics">in vitro </span>human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and <span class="Italics">in vivo </span>mouse micronucleus assays to detect clastogenicity.</p>
<p>There was no impairment of fertility in male or female rats given up to 60 mg sildenafil/kg/day, a dose producing a total systemic exposure (AUC) to unbound sildenafil and its major metabolite of 19 and 38 times for males and females, respectively, the human exposure at the RHD of 20 mg TID.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e102c31-375c-457e-b5c7-282f5ec21a5f"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Italics">Study 1 </span></p>
<p>A randomized, double-blind, placebo-controlled study was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure of ≥ 25 mmHg at rest with a pulmonary capillary wedge pressure &lt; 15 mmHg). Patients were predominantly functional classes II–III. Allowed background therapy included a combination of anticoagulants, digoxin, calcium channel blockers, diuretics, and oxygen. The use of prostacyclin analogues, endothelin receptor antagonists, and arginine supplementation were not permitted. Subjects who had failed to respond to bosentan were also excluded. Patients with left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> &lt; 45% or left ventricular shortening fraction &lt; 0.2 also were not studied. </p>
<p>Patients were randomized to receive placebo (n=70) or REVATIO 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) TID for a period of 12 weeks. They had either PPH (63%), PAH associated with CTD (30%), or PAH following surgical repair of left-to-right congenital heart lesions (7%). The study population consisted of 25% men and 75% women with a mean age of 49 years (range: 18–81 years) and baseline 6-minute walk distance between 100 and 450 meters (mean 343). </p>
<p>The primary efficacy endpoint was the change from baseline at week 12 in 6-minute walk distance at least 4 hours after the last dose. Placebo-corrected mean increases in walk distance of 45–50 meters were observed with all doses of REVATIO. These increases were significantly different from placebo, but the dose groups were not different from each other (Figure 1), indicating no additional clinical benefit from doses higher than 20 mg TID. The improvement in walk distance was apparent after 4 weeks of treatment and was maintained at week 8 and week 12.</p>
<p><span class="Bold">Figure 1. Change from Baseline in 6-Minute Walk Distance (meters): Mean (95% Confidence Interval)</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-02.jpg"></p>
<p>Pre-defined subpopulations in the study were also evaluated for efficacy, including patient differences in baseline walk distance, disease etiology, functional class, gender, age, and secondary hemodynamic parameters (Figure 2). </p>
<p><span class="Bold">Figure 2. Placebo Corrected Change From Baseline in 6-Minute Walk Distance (meters) by study subpopulation: Mean (95% Confidence Interval)</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-03.jpg"></p>
<p><span class="Underline">Key:</span> PAH = <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>; CTD = connective tissue disease; PH = <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; PAP = pulmonary arterial pressure; PVRI = pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> index; TID = three times daily.</p>
<p>Patients on all REVATIO doses achieved a statistically significant reduction in mean pulmonary arterial pressure (mPAP) compared to those on placebo. Data from other hemodynamic parameters can be found in Table 3. The relationship between these effects and improvements in 6-minute walk distance is unknown.</p>
<a name="table3"></a><table>
<caption><span>Table 3. Changes from Baseline to Week 12 in Hemodynamic Parameters at REVATIO 20 mg TID Dose</span></caption>
<col align="center" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">PARAMETER<br> [mean (95% CI)]</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo<br> (n = 65)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">REVATIO 20 mg TID<br> (n = 65)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>The number of patients per treatment group varied slightly for each parameter due to missing assessments.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">mPAP (mmHg)</span></td>
<td class="Rrule" align="left" valign="top">0.6 (-0.8, 2.0)</td>
<td class="Rrule" align="left" valign="top">-2.1 (-4.3, 0.0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">PVR (dyn∙s/cm<span class="Sup">5</span>)</span></td>
<td class="Rrule" align="left" valign="top">49 (-54, 153)</td>
<td class="Rrule" align="left" valign="top">-122 (-217, -27)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">SVR (dyn∙s/cm<span class="Sup">5</span>)</span></td>
<td class="Rrule" align="left" valign="top">-78 (-197, 41)</td>
<td class="Rrule" align="left" valign="top">-167 (-307, -26)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">RAP (mmHg)</span></td>
<td class="Rrule" align="left" valign="top">0.3 (-0.9, 1.5)</td>
<td class="Rrule" align="left" valign="top">-0.8 (-1.9, 0.3)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">CO (L/min)</span></td>
<td class="Rrule" align="left" valign="top">-0.1 (-0.4, 0.2)</td>
<td class="Rrule" align="left" valign="top">0.4 (0.1, 0.7)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">HR (beats/min)</span></td>
<td class="Rrule" align="left" valign="top">-1.3 (-4.1, 1.4)</td>
<td class="Rrule" align="left" valign="top">-3.7 (-5.9, -1.4)</td>
</tr>
</tbody>
</table>
<p>Of the 277 treated patients, 259 entered a long-term, uncontrolled extension study. At the end of 1 year, 94% of these patients were still alive. Additionally, walk distance and functional class status appeared to be stable in patients taking sildenafil. Without a control group, these data must be interpreted cautiously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48083f2d-787a-44ee-8bc9-0079584b1bbd"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Italics">Study 2 </span></p>
<p>A randomized, double-blind, placebo controlled study was conducted in 267 patients with PAH who were stabilized on intravenous epoprostenol. Patients had to have a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg at rest via right heart catheterization within 21 days before randomization, and a baseline 6-minute walk test distance ≥ 100 m and ≤ 450 m (mean 349). Patients were randomized to placebo or REVATIO (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day) when used in combination with intravenous epoprostenol</p>
<p>Patients had <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> (80%) or PAH secondary to CTD (20%). Patients had WHO functional class I (1%), II (26%), III (67%), or IV (6%) at baseline. The mean age was 48 years, 80% were female, and 79% were Caucasian. </p>
<p>Analysis of the primary endpoint showed that there was a statistically significant greater increase in 6-minute walk distance for the REVATIO group compared with the placebo group at Week 16. The mean change from baseline at Week 16 (last observation carried forward) was 30 m for the sildenafil group compared with 4 m for the placebo group giving an adjusted treatment difference of 26 m (95% CI: 10.8, 41.2) (p = 0.0009).</p>
<p>Patients on sildenafil achieved a statistically significant reduction in mPAP compared to those on placebo. A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of REVATIO (95% CI: -5.7, -2.1) (p = 0.00003).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e64b3156-d60c-4db4-8777-6f45ac2e50d1"></a><a name="section-13.3"></a><p></p>
<p class="First"><span class="Italics">Clinical Worsening</span></p>
<p>Time to clinical worsening of PAH was defined as the time from randomization to the first occurrence of a clinical worsening event (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Patients with clinical worsening events are summarized in Table 4. Kaplan-Meier estimates and a stratified log-rank test demonstrated that placebo patients were 3 times more likely to experience an event and that patients receiving REVATIO experienced a significant delay in time to clinical worsening versus placebo (p = 0.0074).</p>
<a name="table4"></a><table>
<caption><span>Table 4. Clinical Worsening Events</span></caption>
<col align="left" width="40%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">Placebo<br>(N = 131)</td>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">REVATIO<br>(N = 134)</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Number of subjects with clinical worsening event n (%)</td>
<td class="Rrule" align="left" colspan="2" valign="top">23 (17.6)</td>
<td class="Rrule" align="left" colspan="2" valign="top">8 (6.0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Incidence of Clinical Worsening Events</span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold">First Event</span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold">All Events</span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold">First Event</span></td>
<td class="Rrule" align="left" valign="top"><span class="Bold">All Events</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">4</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Lung Transplantation</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Hospitalization due to PAH</span></td>
<td class="Rrule" align="left" valign="top">9</td>
<td class="Rrule" align="left" valign="top">11</td>
<td class="Rrule" align="left" valign="top">8</td>
<td class="Rrule" align="left" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Clinical deterioration resulting in:</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="Bold">Change of Epoprostenol Dose</span>
</td>
<td class="Rrule" align="left" valign="top">9</td>
<td class="Rrule" align="left" valign="top">16</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="Bold">Initiation of Bosentan Therapy</span>
</td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Proportion Worsened<br>95% Confidence Intervals</span></td>
<td class="Rrule" align="left" colspan="2" valign="top"><span class="Bold">0.187<br>(0.12 – 0.26)</span></td>
<td class="Rrule" align="left" colspan="2" valign="top"><span class="Bold">0.062<br>(0.02 – 0.10)</span></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3. Kaplan-Meier Plot of Time to Clinical Worsening (Days), ITT Population</span></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-04.jpg"></p>
<p>Improvements in functional class were also demonstrated in subjects on sildenafil compared to placebo. More than twice as many sildenafil treated patients (36%) as the placebo group (14%) showed an improvement of at least one functional class.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">REVATIO tablets are supplied as white, film-coated, round tablets containing sildenafil citrate equivalent to the nominally indicated amount of sildenafil as follows:</p>
<a name="id_d16e383e-f2ab-40ac-8d7b-9b3dd6f6dd57"></a><table>
<caption><span>REVATIO Tablets</span></caption>
<col align="left" width="25%">
<col align="left" width="25%">
<col align="left" width="25%">
<col align="left" width="25%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Package Configuration</td>
<td class="Botrule Rrule" align="left" valign="top">Strength</td>
<td class="Botrule Rrule" align="left" valign="top">NDC</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Engraving on Tablet</td>
</tr></thead>
<tbody><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">Bottle of 90 Tablets</td>
<td class="Rrule" align="left" valign="top">20 mg</td>
<td class="Rrule" align="left" valign="top">0069-4190-68</td>
<td class="Rrule" align="left" valign="top">RVT20</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_2f442863-f59b-40cf-a6e4-07ea9efd209c"></a><a name="section-14.1"></a><p></p>
<p class="First">Recommended Storage for REVATIO Tablets: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_duplicate_id_ad88d6e6-ef7f-4d06-9b98-eec37a287841"></a><a name="section-14.2"></a><p></p>
<p class="First">REVATIO Injection is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg sildenafil (12.5mL) presented in a glass vial.</p>
<a name="id_4b1ce2a5-49f0-4b30-8cf6-b8fd893e0305"></a><table>
<caption><span>REVATIO Injection</span></caption>
<col align="left" width="34%">
<col align="left" width="33%">
<col align="left" width="33%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Package Configuration</td>
<td class="Botrule Rrule" align="left" valign="top">Strength</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">NDC</td>
</tr></thead>
<tbody><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">Vial individually packaged in a carton</td>
<td class="Rrule" align="left" valign="top">10 mg (12.5 mL)</td>
<td class="Rrule" align="left" valign="top">0069-0338-01</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_c8ff5f91-c40c-4a05-8467-67880231da9f"></a><a name="section-14.2.1"></a><p></p>
<p class="First">Recommended Storage for REVATIO Injection: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_s17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul>
<li>Inform patients of contraindication of REVATIO with regular and/or intermittent use of organic nitrates.</li>
<li>Inform patients that sildenafil is also marketed as VIAGRA for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. Advise patients taking REVATIO not to take VIAGRA or other PDE5 inhibitors.</li>
<li>Advise patients to seek immediate medical attention in the event of a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes while taking REVATIO. Such an event may be a sign of NAION.</li>
<li>Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking REVATIO. These events may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73f44de5-acb9-44d0-8d66-d4d44c876530"></a><a name="section-16"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-05.jpg"></p>
<p>LAB-0313-12<br>NOVEMBER - 2010</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_2bf05de4-059c-4d41-9d74-a4bce23710a6"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">REVATIO®</span> (re-VAH-tee-oh)<br>(sildenafil) tablets</p>
<p>Read the Patient Information that comes with REVATIO before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about REVATIO, ask your doctor or pharmacist. </p>
<p><span class="Bold">What is the most important information I should know about REVATIO (sildenafil)?</span></p>
<p><span class="Bold">Never take REVATIO with any nitrate medicines. Your blood pressure could drop quickly. It could <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> to an unsafe level. Nitrate medicines include:</span></p>
<p><span class="Bold">Medicines that treat <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina)</span></p>
<p><span class="Bold">Nitroglycerin in any form</span></p>
<p><span class="Bold">Isosorbide mononitrate or dinitrate</span></p>
<p><span class="Bold">Street drugs called "poppers" (amyl nitrate or nitrite)</span></p>
<p>Ask your doctor or pharmacist if you are not sure if you are taking a nitrate medicine. </p>
<p><span class="Bold">What is REVATIO (sildenafil)? </span></p>
<p>REVATIO is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH). With PAH, the blood pressure in your lungs is too high. Your heart has to work hard to pump blood into your lungs. </p>
<p>REVATIO improves the ability to exercise and can help lessen symptoms and slow down worsening changes in your physical condition. </p>
<p>REVATIO has not been studied</p>
<ul>
<li>in children under 18 years old</li>
<li>in patients who are also taking a medicine called bosentan (Tracleer®)</li>
</ul>
<p>REVATIO contains the same medicine as VIAGRA® (sildenafil), which is used to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>). Do not take REVATIO with VIAGRA or other PDE5 inhibitors.</p>
<p><span class="Bold">Who should not take REVATIO (sildenafil)? </span></p>
<p>Do not take REVATIO if you</p>
<ul>
<li>take nitrate medicines. See "<span class="Underline">What is the most important information I should know about REVATIO?</span>"</li>
<li>are allergic to sildenafil or any other ingredient in REVATIO. See "<span class="Underline">What are the ingredients in REVATIO?</span><a href="#i4i_p_ID_ingredients"></a>" at the end of this leaflet.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking REVATIO (sildenafil)?</span></p>
<p>Tell your doctor about all of your medical conditions, including if you</p>
<ul>
<li>have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or irregular heartbeats in the last 6 months</li>
<li>have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (angina)</li>
<li>have a disease called pulmonary veno-occlusive disease (PVOD)</li>
<li>have high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> or blood circulation problems</li>
<li>have an eye problem called <span class="product-label-link" type="condition" conceptid="4103381" conceptname="Retinitis pigmentosa">retinitis pigmentosa</span></li>
<li>have or had loss of sight in one or both eyes</li>
<li>have liver or kidney problems</li>
<li>have any problem with the shape of your penis</li>
<li>lose a large amount of body fluids (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>). This can happen if you are sick with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> can also happen when you sweat a lot or don't drink enough liquids.</li>
<li>have any blood cell problems such as cancer of blood cells or bone marrow or <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span></li>
<li>have a <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span> or any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>are pregnant or planning to become pregnant. It is not known if REVATIO could harm your unborn baby.</li>
<li>are breastfeeding. It is not known if REVATIO passes into your breast milk or if it could harm your baby.</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal products.</span> REVATIO and certain other medicines can cause side effects if you take them together. The doses of some of your medicines may need to be adjusted while you take REVATIO. </p>
<p> Especially tell your doctor if you </p>
<ul>
<li>Take nitrate medicines. See "<span class="Bold"><span class="Underline">What is the most important information I should know about REVATIO?</span></span>"</li>
<li>Take ritonavir (Norvir<span class="Sup">®</span>) or other medicines used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span></li>
<li>Use ketoconazole (Nizoral<span class="Sup">®</span>)</li>
</ul>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take REVATIO (sildenafil)?</span></p>
<ul>
<li>Take REVATIO exactly as your doctor tells you.</li>
<li>REVATIO is a tablet you take by mouth. Take a REVATIO tablet 3 times a day about 4 to 6 hours apart.</li>
<li>Take REVATIO at the same times every day, with or without food.</li>
<li>If you miss a dose, take it as soon as you remember. If it is close to your next dose, skip the missed dose, and take your next dose at the regular time.</li>
<li>Do not take more than one dose of REVATIO at a time.</li>
<li>Do not change your dose or stop taking REVATIO on your own. Talk to your doctor first.</li>
<li><span class="Bold">If you take too much REVATIO, call your doctor or poison control center, or go to an emergency room.</span></li>
</ul>
<p><span class="Bold">What are the possible side effects of REVATIO (sildenafil)?</span></p>
<p><span class="Bold">The following side effects were reported in patients taking sildenafil.</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>. </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> may cause you to feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy.</li>
<li>
<span class="Bold">more <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> than usual. </span>Tell your doctor if you get more <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span> after you start REVATIO. More <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> than usual may be due to your underlying medical condition.</li>
<li>
<span class="Bold">decreased eyesight or loss of sight in one or both eyes (NAION).</span> If you notice a sudden decrease or loss of eyesight, talk to your doctor right away. It is not possible to determine if these events are related to oral medicines for the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, including sildenafil, or to other medical problems, or combination of these factors.</li>
<li>
<span class="Bold">sudden decrease or loss of hearing. </span>If you notice a sudden decrease or loss of hearing, talk to your doctor right away. It is not possible to determine whether these events are related directly to this class of oral medicines, including sildenafil, or to other diseases or medications, to other factors, or to a combination of factors.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, irregular heartbeats, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> Most of these happened in men who already had heart problems.</li>
<li>
<span class="Bold">erections that last several hours. </span>Tell your doctor right away if you have an erection that lasts more than 4 hours.</li>
</ul>
<p><span class="Bold">The most common side effects with REVATIO include:</span><br><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Nosebleed</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, getting red or hot in the face (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>), and trouble sleeping. </p>
<p><span class="Bold"><span class="Italics">Tell your doctor if you have any side effect that bothers you or doesn't go away.</span></span></p>
<p><span class="Bold"><span class="Italics">These are not all the possible side effects of REVATIO. For more information, ask your doctor or pharmacist. </span></span></p>
<p><span class="Bold">How should I store REVATIO (sildenafil)?</span></p>
<ul>
<li>Store REVATIO at room temperature, 59–86°F (15–30°C).</li>
<li><span class="Bold">Keep REVATIO and all medicines away from children.</span></li>
</ul>
<p><span class="Bold">General information about REVATIO (sildenafil)</span></p>
<p>Medicines are sometimes prescribed for conditions that are not in the patient leaflet. Do not use REVATIO for a condition for which it was not prescribed. Do not give REVATIO to other people, even if they have the same symptoms you have. It could harm them. </p>
<p>This patient leaflet summarizes the most important information about REVATIO. If you would like more information about REVATIO: </p>
<ul>
<li>Ask your doctor or pharmacist for information about REVATIO that is written for health professionals.</li>
<li>Go to <span class="Bold">www.REVATIO.com </span>or call <span class="Bold">1-800-879-3477.</span>
</li>
</ul>
<p><span class="Bold">What are the ingredients in REVATIO (sildenafil)?</span></p>
<p>REVATIO Tablets</p>
<p><span class="Bold">Active ingredients:</span> sildenafil citrate</p>
<p><span class="Bold">Inactive ingredients: </span>microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, lactose monohydrate, and triacetin</p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-06.jpg"></p>
<p>LAB-0335-5.0<br>NOVEMBER – 2009</p>
<p>REVATIO 20 mg tablets are available from Cardinal Health in unit dose packages of 90 tablets</p>
<p>20 mg, unit dose package of 90, NDC 55154-2729-4</p>
<p>Cardinal Health</p>
<p>Zanesville OH 43701</p>
<p>IU40285280511</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d31fd7c1-23c1-4e91-96b3-3194b6d6cdde"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel-Carton</h1>
<p class="First">NDC: 55154-2729-4</p>
<p>Revatio</p>
<p>(sildenafil) Tablet</p>
<p>20 mg*</p>
<p>90 Tablets</p>
<p>*Each tablet contains sildenafil citrate equivalent to 20 mg sildenafil.</p>
<p>See product insert for dosage, use, prescribing information, precautions and warnings.</p>
<p>STORAGE: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in tight containers (USP).</p>
<p>RX ONLY</p>
<p>WARNING: This package is intended for institutional use only.  This package is not child resistant. Keep this and all drugs out of the reach of children.</p>
<p>See window for lot number and expiration date.</p>
<p>Distributed by: Pfizer Labs</p>
<p>Division of Pfizer Inc.</p>
<p>NY, NY 10017</p>
<p>MADE IN FRANCE</p>
<p>Repackaged by: Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>LUC40285280710</p>
<div class="Figure"><img alt="Revatio Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9c0f73ec-189c-4020-96c9-59034fb1d7b2"></a><a name="section-19"></a><p></p>
<h1>Principal Display Panel-Pouch</h1>
<p class="First">Revatio®</p>
<p>(sildenafil) Tablet</p>
<p>20 mg</p>
<div class="Figure"><img alt="Revatio Pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1fdd7a6c-9702-4af8-85ac-76a0aa8b9481"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - BAG</h1>
<p class="First">Revatio®</p>
<p>Sildenafil Tablets</p>
<p>20 mg*</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f757f066-8288-4d6c-8c5e-2471007c7966&amp;name=77af9ffd-f15f-4cf5-acad-446765d1f7f4-09.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REVATIO 		
					</strong><br><span class="contentTableReg">sildenafil citrate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2729(NDC:0069-4190)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sildenafil citrate</strong> (sildenafil) </td>
<td class="formItem">sildenafil</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PFIZER;RVT20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2729-4</td>
<td class="formItem">90  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2729-6</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-2729-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021845</td>
<td class="formItem">06/03/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-2729)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>77af9ffd-f15f-4cf5-acad-446765d1f7f4</div>
<div>Set id: f757f066-8288-4d6c-8c5e-2471007c7966</div>
<div>Version: 3</div>
<div>Effective Time: 20120627</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
